rly-2608

Small moleculeexperimental

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Dec 8, 2021 (NCT05216432)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N#Cc1c(-c2cc(NC(=O)c3cc(F)cc(C(F)(F)F)c3)c3c(c2)C(=O)N[C@H]3c2cc(F)ccc2Cl)ccc2ncnn12
Mol. weight
608.91 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06982521Phase 3Aug 26, 2025Relay Therapeutics, Inc.
NCT06789913Phase 2Mar 31, 2025Relay Therapeutics, Inc.
NCT05216432Phase 1Dec 8, 2021Relay Therapeutics, Inc.
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Relay Therapeutics, Inc.For profit3332021
1 organizations
Page 1 / 1